Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor. Giving bendamustine together with erlotinib
may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving
bendamustine together with erlotinib in treating patients with stage IIIB, stage IIIC, or
stage IV breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center Rachel Layman
Collaborators:
Genentech, Inc. National Comprehensive Cancer Network